Quick Answer
Aligos Therapeutics, Inc. reported Operating Income Loss of -$87.99 million for the year ending 2025.
- Aligos Therapeutics, Inc. showed an increase of +1.3% in Operating Income Loss from 2024 to 2025.
- This data is from Aligos Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: -$14.50 million | Q1 2020: -$20.72 million | Q2 2020: -$21.27 million | Q3 2020: -$21.56 million | Q1 2021: -$27.74 million | Q2 2021: -$29.57 million | Q3 2021: -$33.07 million | Q1 2022: -$35.56 million | Q2 2022: -$20.39 million | Q3 2022: -$18.95 million | Q1 2023: -$23.92 million | Q2 2023: -$19.14 million | Q3 2023: -$19.07 million | Q1 2024: -$22.05 million | Q2 2024: -$26.41 million | Q3 2024: -$20.13 million | Q1 2025: -$19.24 million | Q2 2025: -$18.57 million | Q3 2025: -$28.36 million.
- Over the full 7 years of available data (2019 to 2025), Aligos Therapeutics, Inc.'s Operating Income Loss has declined by 62.8%.
- Historical annual values: Fiscal year 2025: -$87.99 million | Fiscal year 2024: -$89.15 million | Fiscal year 2023: -$88.13 million | Fiscal year 2022: -$97.58 million | Fiscal year 2021: -$128.32 million | Fiscal year 2020: -$97.83 million | Fiscal year 2019: -$54.04 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: